- |||||||||| Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation-Positive Melanoma: Patient Selection and Perspectives. (Pubmed Central) - Aug 5, 2024 Due to the up-regulation of PD-1/PD-L1 receptors in tumors treated with BRAF/MEK inhibitor therapy, further studies included a third combination agent, anti-PD-1/PD-L1 inhibitors. This triple combination therapy may have superior efficacy and a manageable safety profile when compared with single or double agent therapy regimens.
- |||||||||| BMS-986340 / BMS, Opdivo (nivolumab) / BMS
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: CA052-002: A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 5, 2024 P1/2, N=905, Recruiting, Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024 N=665 --> 905 | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Apr 2025 --> Dec 2025
- |||||||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Opdivo (nivolumab) / BMS
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Surgery, Metastases: Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer (clinicaltrials.gov) - Aug 5, 2024 P1/2, N=0, Withdrawn, Recruiting --> Active, not recruiting N=50 --> 0 | Trial completion date: Dec 2036 --> Aug 2024 | Suspended --> Withdrawn | Trial primary completion date: Dec 2034 --> Aug 2024
- |||||||||| RP3 / Replimune
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours (clinicaltrials.gov) - Aug 5, 2024 P1, N=123, Active, not recruiting, N=50 --> 0 | Trial completion date: Dec 2036 --> Aug 2024 | Suspended --> Withdrawn | Trial primary completion date: Dec 2034 --> Aug 2024 Trial completion date: Apr 2024 --> Nov 2026 | Trial primary completion date: Apr 2024 --> Nov 2026
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (clinicaltrials.gov) - Aug 4, 2024 P1/2, N=30, Active, not recruiting, Trial completion date: Dec 2026 --> Aug 2025 | Trial primary completion date: Dec 2026 --> Apr 2024 Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
- |||||||||| AiRuiKa (camrelizumab) / HLB Bio Group
First Line Camrelizumab for Brain Metastases of NSCLC (CTONG 2003): A Randomized Controlled Trial (Exhibit Hall) - Aug 4, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2700; The study is open for enrollment in centres across the USA, Belgium, Italy, Spain, France, Japan and Korea. Adult treatment-nai?ve NSCLC patients with BM and no EGFR/ALK alterations were randomized at 1:1 to receive camrelizumab (200mg) or placebo, plus platinum-doublet chemotherapy on day 1 of each 3-week cycle for 4-6 cycles, followed by maintenance camrelizumab or placebo
- |||||||||| Imdelltra (tarlatamab-dlle) / Amgen
DeLLphi-306 Trial: A Phase 3 Study of Tarlatamab after Concurrent Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer (Exhibit Hall) - Aug 4, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2696; P3 Other secondary endpoints include investigator-assessed PFS, investigator and BICR-assessed objective response rate, disease control rate, duration of response, time to progression (all per RECIST 1.1), incidence of treatment-emergent and treatment-related adverse events, serum concentrations of tarlatamab, and incidence of anti-tarlatamab antibody formation. This trial is actively recruiting patients.
- |||||||||| nibrozetone (RRx-001) / EpicentRx
Preclinical, Journal, Tumor microenvironment, PD(L)-1 Biomarker, IO biomarker: CD40 agonist engineered immunosomes modulated tumor microenvironment and showed pro-immunogenic response, reduced toxicity, and tumor free survival in mice bearing glioblastoma. (Pubmed Central) - Aug 4, 2024 To overcome these issues, in this study, we have developed a multifunctional Immunosome where ?CD40 is conjugated on the surface and RRX-001, a small molecule immunomodulator was encapsulated inside it...In addition, Immunosomes treated long-term surviving mice showed tumor specific immune memory response which prevented tumor growth upon rechallenge. Our results suggested that this novel formulation can be further explored in clinics to improve in vivo anti-tumor efficacy of ?CD40 with long-lasting tumor specific immunity while reducing the associated toxicities.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), davoceticept (ALPN-202) / Alpine Immune Sci
P1 data, Journal, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). (Pubmed Central) - Aug 4, 2024 P1 However, two fatal cardiac events occurred with the combination of low-dose davoceticept and pembrolizumab. Future clinical investigation with davoceticept should not consider combination with programmed death-1-inhibitor anticancer mechanisms, until its safety profile is more fully elucidated.
- |||||||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: First-Line Treatment with Atezolizumab plus Bevacizumab and Chemotherapy for US Patients with Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis. (Pubmed Central) - Aug 4, 2024 Further research is needed to support the ongoing development of approaches to irAE management. CBA treatment is unlikely to be a cost-effective option compared with CB for patients with persistent, recurrent, or metastatic cervical cancer in the United States.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Renal cell carcinoma. (Pubmed Central) - Aug 4, 2024 Developments in adjuvant therapies are discussed, including use of pembrolizumab-the first therapy to achieve overall survival benefit in the adjuvant setting...Management of non-clear cell renal cell carcinoma subtypes is also reviewed. Future directions of research, including a discussion of ongoing clinical trials and the need for reliable biomarkers to guide treatment in kidney cancer, are also highlighted.
- |||||||||| Bexxar (iodine I 131 tositumomab) / GSK, Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Review, Journal: The Rebirth of Radioimmunotherapy of Non-Hodgkin Lymphoma: The Phoenix of Nuclear Medicine? (Pubmed Central) - Aug 4, 2024 Our findings may pave further in detailed mechanistic study on these complexes as potential chemotherapeutic agents in different types of human cancers. However, despite their therapeutic efficacy, Bexxar
- |||||||||| Review, Journal, HEOR, CAR T-Cell Therapy: Economic Evaluations of CAR-T Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review. (Pubmed Central) - Aug 4, 2024
CAR-T therapies were more expensive and generated more QALYs than comparators, but their cost-effectiveness was uncertain and dependent on patient population, cancer type, and model assumptions. This highlights the need for more nuanced economic evaluations and continued research to better understand the value of CAR-T therapies in diverse patient populations.
|